Revue Prescrire, article en une, Medicines in Europe January 2003 (9)
Prescrire     Accueil  
 
Article en Une - Archive
Medicines in Europe: Situation update, 31 December 2002. Some successes, much work remaining
 
Here we examine the state of play, now that the Commission has published its new draft proposals taking into account the amendments made by the Parliament and Council.
More information
 


Medicines in Europe: campaigning goes on!
Click here

Transparency of the European Medicines Evaluation Agency (EMEA)
Click here

Functioning of the agency
Click here

Drug evaluation
Click here

Pharmacovigilance
Click here

Compassionate use
Click here

Download (English, file type: zip)
thematic.zip

Data protection

We regret:
• the Commission rejected an amendment recommending that individual Member States need not be bound by the 10-year data protection period (some currently protect data for only 6 years) (amendment 46, article 138).

Developing countries

Pathetic:
• the Commission rejected all amendments calling for active solidarity with poor countries, including exportation restricted to drugs with proven efficacy, safety and quality; research incentives for diseases affecting the poorest countries; co-operation on pharmaceuticals, etc. (amendments 7, 8, 26 and 94). The Commission considered that such proposals were outside the scope of the draft Regulation.

Pricing

Cause for concern:
the Commission accepted to apply the rule whereby drug pricing negotiations between companies and national authorities should not exceed 180 days (amendments 15 and 47, considering 30bis, article 13bis).

©La revue Prescrire 15 January 2003